Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4271867 | The Journal of Sexual Medicine | 2009 | 13 Pages |
Abstract
Antagonizing TGF-β signaling through the use of ALK5 inhibitors may represent an exciting new therapeutic strategy for the future treatment of PD. Ryu J-K, Piao S, Shin H-Y, Choi MJ, Zhang LW, Jin H-R, Kim WJ, Han J-Y, Hong SS, Park SH, Lee S-J, Kim I-H, Lee CR, Kim D-K, Mamura M, Kim S-J, and Suh J-K. IN-1130, a novel transforming growth factor-β type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009;6:1284-1296.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Ji-Kan MD, PhD, Shuguang MD, PhD, Hwa-Yean MS, Min Ji MS, Lu Wei MD, PhD, Hai-Rong MD, Woo Jean PhD, Jee-Young MD, PhD, Soon Sun PhD, Seok Hee PhD, Sang-Jin PhD, In-Hoo MD, PhD, Chung Ryul PhD, Dae-Kee PhD, Mizuko MD, PhD, Seong-Jin PhD, Jun-Kyu MD, PhD,